Wanying Li1, Liuning Li2. 1. The Second Clinical College, Guangzhou University of CM, Guangzhou 510000, Guangdong Province, China. 2. The Third Department of Internal Medicine, Guangdong Provincial Hospital of TCM, Guangzhou 510000.
Abstract
OBJECTIVE: To observe the clinical effects between moxibustion combined with 5-hydroxy tryptamine (5-HT) receptor antagonist and simple 5-HT receptor antagonist in the prevention and treatment of nausea and vomiting caused by cisplatin chemotherapy in patients with lung cancer. METHODS:Fifty-eight patients with lung cancer who were treated withcisplatin chemotherapy were randomly assigned into an observation group and a control group, 29 cases in each one. The patients in the two groups were applied by 5-HT receptor antagonist to prevent nausea and vomiting on the 1st through 3rd days of chemotherapy. Moxibustion at Baihui (GV 20) and Zhongwan (CV 12) was used in the observation group 1-3 days before chemotherapy for 1 course, 3 days as 1 course, 5 cones each acupoint and once a day. Rhodes's index of nausea and vomiting and retching (INVR) was recorded in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy. The rates of nausea and vomiting, as well as fatigue degree were observed in the above 4 time periods. The safety was assessed. RESULTS: After treatment, the scores of nausea and vomiting in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy in the observation group were lower than those in the control group (all P<0.01). The nausea rates in the above 4 time periods in the observation group were 37.9% (11/29), 62.1% (18/29), 60.7% (17/28) and 17.4% (4/23), which were lower than 93.1% (27/29), 89.7% (26/29), 89.3% (25/28), 52.0% (13/25) in the control group respectively (all P<0.05). The vomiting rates in the above 4 time periods in the observation group were 10.3% (3/29), 31.0% (9/29), 32.1% (9/28) and 13.0% (3/23), which were better than 37.9% (11/29), 79.3% (23/29), 82.1% (23/28) and 44.0% (11/25) in the control group (all P<0.05). The fatigue scores in the observation group in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy were lower than those in the control group (all P<0.01). There was no adverse reactions in the two groups during chemotherapy, such as skin toxicity, diarrhea, fever, allergy, etc. CONCLUSION:Moxibustion combined with 5-HT receptor antagonist can obviously reduce the rates and degrees of nausea and vomiting caused by cisplatin chemotherapy in patients with lung cancer, which are better than simple 5-HT receptor antagonist, without apparent adverse reactions.
RCT Entities:
OBJECTIVE: To observe the clinical effects between moxibustion combined with 5-hydroxy tryptamine (5-HT) receptor antagonist and simple 5-HT receptor antagonist in the prevention and treatment of nausea and vomiting caused by cisplatin chemotherapy in patients with lung cancer. METHODS: Fifty-eight patients with lung cancer who were treated with cisplatin chemotherapy were randomly assigned into an observation group and a control group, 29 cases in each one. The patients in the two groups were applied by 5-HT receptor antagonist to prevent nausea and vomiting on the 1st through 3rd days of chemotherapy. Moxibustion at Baihui (GV 20) and Zhongwan (CV 12) was used in the observation group 1-3 days before chemotherapy for 1 course, 3 days as 1 course, 5 cones each acupoint and once a day. Rhodes's index of nausea and vomiting and retching (INVR) was recorded in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy. The rates of nausea and vomiting, as well as fatigue degree were observed in the above 4 time periods. The safety was assessed. RESULTS: After treatment, the scores of nausea and vomiting in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy in the observation group were lower than those in the control group (all P<0.01). The nausea rates in the above 4 time periods in the observation group were 37.9% (11/29), 62.1% (18/29), 60.7% (17/28) and 17.4% (4/23), which were lower than 93.1% (27/29), 89.7% (26/29), 89.3% (25/28), 52.0% (13/25) in the control group respectively (all P<0.05). The vomiting rates in the above 4 time periods in the observation group were 10.3% (3/29), 31.0% (9/29), 32.1% (9/28) and 13.0% (3/23), which were better than 37.9% (11/29), 79.3% (23/29), 82.1% (23/28) and 44.0% (11/25) in the control group (all P<0.05). The fatigue scores in the observation group in 0-24 h, 24-48 h, 48-72 h and 72-96 h of chemotherapy were lower than those in the control group (all P<0.01). There was no adverse reactions in the two groups during chemotherapy, such as skin toxicity, diarrhea, fever, allergy, etc. CONCLUSION: Moxibustion combined with 5-HT receptor antagonist can obviously reduce the rates and degrees of nausea and vomiting caused by cisplatin chemotherapy in patients with lung cancer, which are better than simple 5-HT receptor antagonist, without apparent adverse reactions.
Entities:
Keywords:
Point CV 12 (Zhongwan); Point GV 20 (Baihui); chemotherapy; cisplatin; lung cancer; moxibustion; nausea and vomiting